Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CSTL

Castle Biosciences Inc

Feb 05 • 11:52AM ET

28.28

Dollar change +0.13
Percentage change 0.46	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: GH EXAS FLGT CDNA MYGN NTRA QDEL DGX ILMN TXG

| Held by: VTI IWM VXF IBB IWN DFAT SCHA VTWO VHT IWO

Scroll to Statements

Index	RUT	P/E	141.47	EPS (ttm)	0.20	Insider Own	3.10%	Shs Outstand	27.98M	Perf Week	2.87%
Market Cap	792.05M	Forward P/E	-	EPS next Y	-1.79	Insider Trans	-17.40%	Shs Float	27.14M	Perf Month	-1.15%
Income	6.08M	PEG	10.44	EPS next Q	0.05	Inst Own	91.92%	Short Float	6.16%	Perf Quarter	-14.69%
Sales	311.88M	P/S	2.54	EPS this Y	118.31%	Inst Trans	0.63%	Short Ratio	4.25	Perf Half Y	29.43%
Book/sh	15.77	P/B	1.79	EPS next Y	-555.81%	ROA	1.28%	Short Interest	1.67M	Perf Year	20.80%
Cash/sh	9.99	P/C	2.83	EPS next 5Y	13.55%	ROE	1.47%	52W Range	16.97 - 35.84	Perf YTD	6.12%
Dividend Est.	-	P/FCF	19.79	EPS past 5Y	-28.57%	ROI	1.30%	52W High	-21.09%	Beta	0.94
Dividend TTM	-	Quick Ratio	7.64	Sales past 5Y	44.25%	Gross Margin	78.43%	52W Low	66.70%	ATR (14)	1.45
Dividend Ex-Date	-	Current Ratio	7.78	EPS Y/Y TTM	107.63%	Oper. Margin	-0.33%	RSI (14)	53.12	Volatility	3.69% 6.68%
Employees	610	Debt/Eq	0.06	Sales Y/Y TTM	62.43%	Profit Margin	1.95%	Recom	1.11	Target Price	40.67
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	130.00%	Payout	-	Rel Volume	0.99	Prev Close	28.15
Sales Surprise	7.43%	EPS Surprise	2100.00%	Sales Q/Q	39.50%	Earnings	Nov 04 AMC	Avg Volume	393.57K	Price	28.28
SMA20	2.66%	SMA50	-0.59%	SMA200	6.10%	Trades		Volume	154,922	Change	0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Guggenheim	Buy	$25
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$54
Jan-07-22	Initiated	Stephens	Overweight	$59
Apr-30-21	Initiated	Lake Street	Buy	$94
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$70
Dec-27-19	Reiterated	Canaccord Genuity	Buy	$34 → $35
Aug-19-19	Initiated	SVB Leerink	Outperform	$28
Aug-19-19	Initiated	Robert W. Baird	Outperform	$27
Aug-19-19	Initiated	Canaccord Genuity	Buy	$26
Aug-19-19	Initiated	BTIG Research	Buy	$25

Jan-29-25 09:55AM	Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet (Zacks)
Jan-17-25 07:00AM	Castles Poster on DecisionDx-SCC Selected as a Late Breakers Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025 (Business Wire)
Jan-12-25 06:00PM	Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results (Business Wire)
Jan-06-25 11:15AM	Castle Biosciences gains New York state approval for Barretts oesophagus test (Medical Device Network)
07:00AM	Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher Barretts Esophagus Test (Business Wire)
08:10AM	Loading…
Dec-24-24 08:10AM	Castle Biosciences reports preliminary data from atopic dermatitis test study (Medical Device Network)
Dec-23-24 07:00AM	Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test (Business Wire)
Dec-19-24 07:00AM	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-16-24 09:55AM	Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade (Zacks)
Dec-12-24 07:00AM	Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences DecisionDx-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma (Business Wire)
Nov-20-24 07:00AM	Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-19-24 07:00AM	Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year (Business Wire)
Nov-08-24 08:50AM	Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
07:00AM	Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx-Melanoma and MyPath Melanoma at the American Society of Dermatopathology 61st Annual Meeting (Business Wire)
Nov-07-24 12:00PM	Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why (Zacks)
07:52AM	Loading…
07:52AM	Castle boasts melanoma tests capacity to reduce unnecessary testing (Medical Device Network)
07:00AM	Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher Barretts Esophagus Test (Business Wire)
Nov-06-24 07:00AM	Use of Castle Biosciences DecisionDx-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024 (Business Wire)
06:45AM	Castle Biosciences price target raised to $39 from $37 at Baird (TipRanks)
06:25AM	Castle Biosciences price target raised to $36 from $28 at KeyBanc (TipRanks)
Nov-05-24 02:00PM	Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) -7.40%
Nov-04-24 05:50PM	Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:05PM	Castle Biosciences Reports Third Quarter 2024 Results (Business Wire)
Nov-01-24 09:15AM	Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue? (Zacks)
09:05AM	Castle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:30PM	Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher Test to Significantly Reduce Healthcare Costs Associated with the Management of Barretts Esophagus Patients (Business Wire)
Oct-28-24 07:00AM	Castle Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Oct-23-24 08:50AM	Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going (Zacks)
Oct-22-24 12:00PM	Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy? (Zacks)
Oct-20-24 05:00AM	Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors (Business Wire)
07:00AM	Loading…
Oct-16-24 07:00AM	Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential (Business Wire)
Oct-15-24 09:15AM	Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out? (Zacks)
07:30AM	Castle Biosciences price target raised to $40 from $35 at BTIG (TipRanks)
04:47AM	Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength? (Zacks)
Oct-14-24 07:00AM	Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024 (Business Wire) +9.42%
Oct-11-24 07:00AM	Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin (Business Wire) +10.64%
Oct-09-24 03:58PM	Castle Biosciences Inc (CSTL) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
07:00AM	New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences DecisionDx-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions (Business Wire)
Oct-07-24 12:00PM	Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Oct-02-24 07:00AM	Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas (Business Wire)
Sep-27-24 05:15PM	New Data at ASTRO 2024 Shows Castle Biosciences DecisionDx-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma (Business Wire)
Sep-23-24 07:00AM	New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences TissueCypher Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barretts Esophagus (Business Wire)
Sep-16-24 07:00AM	Castle Biosciences Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year (Business Wire)
Sep-11-24 07:00AM	DecisionDx-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms (Business Wire) +5.90%
Sep-05-24 07:02PM	Insider Sale: COO Kristen Oelschlager Sells Shares of Castle Biosciences Inc (CSTL) (GuruFocus.com)
07:00AM	Study Confirms the Ability of Castle Biosciences' DecisionDx-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma (Business Wire)
Aug-28-24 07:00AM	Castle Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Aug-05-24 05:45PM	Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates (Zacks) +13.96%
04:05PM	Castle Biosciences Reports Second Quarter 2024 Results (Business Wire)
Jul-30-24 07:00AM	Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference (Business Wire) +7.72%
Jul-29-24 10:00AM	Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-22-24 07:00AM	Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma (Business Wire)
Jul-15-24 07:00AM	Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024 (Business Wire)
Jul-12-24 12:00PM	All You Need to Know About Castle Biosciences (CSTL) Rating Upgrade to Strong Buy (Zacks)
Jul-11-24 07:00AM	Castle Biosciences Honored with Top Workplaces Awards (Business Wire) +5.78%
Jun-24-24 07:00AM	Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences TissueCypher Test (Business Wire)
Jun-20-24 07:00AM	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-14-24 04:30PM	Castle Biosciences Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year 2024 Gulf South Award Winner (Business Wire)
Jun-13-24 09:40AM	Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year? (Zacks)
May-30-24 04:30PM	Castle Biosciences to Present New Data at 2024 ASCO Annual Meeting Highlighting Use of DecisionDx-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance (Business Wire)
May-29-24 04:30PM	New Publication Shows DecisionDx-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis (Business Wire)
May-23-24 09:55AM	Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect? (Zacks)
08:50AM	What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' (Zacks)
May-15-24 07:00AM	Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference (Business Wire)
May-14-24 07:00AM	Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher Barretts Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024 (Business Wire)
May-10-24 07:00AM	Castle Biosciences IDgenetix Test Receives 2024 MedTech Breakthrough Award for Best Overall Mental Health Solution (Business Wire)
May-08-24 05:22PM	Castle Biosciences Insider Sold Shares Worth $574,679, According to a Recent SEC Filing (MT Newswires)
04:30PM	Largest Prospective Study to Date Further Supports Performance of DecisionDx-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result (Business Wire)
May-07-24 09:55AM	Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should Know (Zacks)
May-06-24 08:50AM	Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
May-05-24 08:32AM	Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 07:00AM	DecisionDx-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck (Business Wire) +6.52%
May-02-24 08:56PM	CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:59PM	Castle Biosciences Inc (CSTL) Q1 2024 Earnings: Surpasses Revenue Forecasts and Raises Annual ... (GuruFocus.com)
05:50PM	Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Castle Biosciences Reports First Quarter 2024 Results (Business Wire)
Apr-30-24 04:30PM	Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswoods Designation as a Sun Safe Leadership Model City by IMPACT Melanoma (Business Wire)
Apr-11-24 07:00AM	Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024 (Business Wire)
Apr-10-24 05:00PM	Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations (Business Wire) -5.15%
07:00AM	Castle Biosciences Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year (Business Wire)
Apr-05-24 04:43AM	What Makes Castle Bioscience (CSTL) a Prospective Investment? (Insider Monkey)
Apr-04-24 04:30PM	Presentations at EADO Highlight Potential Impact of Castle Biosciences DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer (Business Wire)
Apr-02-24 07:00AM	Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-27-24 05:00PM	Castle Biosciences Announces Updates to its Board of Directors (Business Wire)
Mar-25-24 07:00AM	Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year (Business Wire)
Mar-22-24 04:30PM	Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB (Business Wire)
Mar-20-24 05:17AM	Does Castle Bioscience (CSTL) Have Robust Growth Prospects? (Insider Monkey) +5.11%
Mar-19-24 07:00AM	Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy (Business Wire)
Mar-15-24 04:30PM	New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences IDgenetix Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older (Business Wire)
Mar-12-24 07:00AM	Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum (Business Wire)
Mar-08-24 04:30PM	Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Mar-07-24 07:00AM	In Novel Cohort, New Data Confirms DecisionDx-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups (Business Wire)
Feb-29-24 10:37AM	Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2023 Earnings Call Transcript (Insider Monkey) -25.95%
08:43AM	Q4 2023 Castle Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-24 06:30PM	Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:40PM	Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:42PM	Castle Biosciences Inc (CSTL) Reports Robust Revenue Growth and Improved Margins in 2023 (GuruFocus.com)
04:05PM	Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results (Business Wire)
Feb-26-24 09:16AM	Insights Into Castle Biosciences, Inc. (CSTL) Q4: Wall Street Projections for Key Metrics (Zacks)
07:00AM	Study Finds DecisionDx-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging (Business Wire)

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 13 '25	Sale	28.03	1,579	44,262	5,104	Jan 15 04:57 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 13 '25	Sale	28.03	986	27,641	80,818	Jan 15 04:57 PM
BRADBURY DANIEL	Director	Jan 06 '25	Sale	29.14	7,867	229,226	1,425	Jan 08 06:19 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 06 '25	Sale	29.62	4,343	128,637	5,291	Jan 08 06:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 06 '25	Sale	29.62	2,715	80,412	82,047	Jan 08 06:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 07 '25	Sale	30.14	388	11,694	5,254	Jan 08 06:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 07 '25	Sale	30.14	243	7,324	81,804	Jan 08 06:18 PM
Juvenal Tobin W	Chief Commercial Officer	Jan 06 '25	Sale	30.00	2,230	66,900	69,943	Jan 08 06:17 PM
TOBIN JUVENAL	Officer	Jan 06 '25	Proposed Sale	28.61	2,230	63,800		Jan 06 04:29 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 17 '24	Sale	28.34	9,364	265,358	84,762	Dec 19 04:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 13 '24	Sale	28.64	13,485	386,209	105,185	Dec 17 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 16 '24	Sale	28.83	11,059	318,864	94,126	Dec 17 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 13 '24	Sale	28.64	1,579	45,223	5,702	Dec 17 04:21 PM
Derek Maetzold	Officer	Dec 13 '24	Proposed Sale	28.87	48,303	1,394,508		Dec 13 05:00 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 05 '24	Sale	31.35	3,155	98,916	5,852	Dec 09 05:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 05 '24	Sale	31.35	1,972	61,826	85,748	Dec 09 05:09 PM
BRADBURY DANIEL	Director	Dec 03 '24	Sale	30.98	7,867	243,693	2,850	Dec 05 04:28 PM
Daniel Bradbury	Officer	Dec 03 '24	Proposed Sale	30.78	15,734	484,293		Dec 03 05:14 PM
Stokes Frank	Chief Financial Officer	Nov 15 '24	Sale	29.93	6,923	207,217	30,823	Nov 19 04:04 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 12 '24	Sale	34.15	3,155	107,743	6,151	Nov 14 06:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 12 '24	Sale	34.15	1,972	67,344	87,720	Nov 14 06:21 PM
Stokes Frank	Officer	Nov 15 '24	Proposed Sale	31.48	6,923	217,936		Nov 14 01:39 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 05 '24	Option Exercise	3.38	3,507	11,854	57,685	Nov 07 04:12 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 05 '24	Sale	35.56	3,507	124,709	54,178	Nov 07 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 04 '24	Sale	32.54	3,155	102,657	6,450	Nov 06 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 04 '24	Sale	32.54	1,972	64,163	89,692	Nov 06 04:21 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 01 '24	Option Exercise	3.38	1,100	3,718	57,278	Nov 05 04:33 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 01 '24	Sale	35.39	3,100	109,709	54,178	Nov 05 04:33 PM
BRADBURY DANIEL	Director	Nov 01 '24	Sale	34.73	7,867	273,251	4,275	Nov 05 04:32 PM
Derek Maetzold	Officer	Nov 04 '24	Proposed Sale	33.64	15,381	517,417		Nov 04 05:34 PM
TOBIN JUVENAL	Officer	Nov 01 '24	Proposed Sale	34.67	12,000	416,040		Nov 01 04:49 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 14 '24	Sale	32.27	3,155	101,821	6,749	Oct 16 04:34 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 14 '24	Sale	32.27	1,972	63,642	91,664	Oct 16 04:34 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 08 '24	Sale	30.27	1,576	47,704	7,048	Oct 10 04:22 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 08 '24	Sale	30.27	986	29,845	93,636	Oct 10 04:22 PM
BRADBURY DANIEL	Director	Oct 07 '24	Sale	29.44	7,867	231,628	5,700	Oct 09 04:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 04 '24	Sale	28.73	1,579	45,371	7,197	Oct 08 04:48 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 04 '24	Sale	28.73	986	28,332	94,622	Oct 08 04:48 PM
Daniel Bradbury	Officer	Oct 07 '24	Proposed Sale	29.52	15,734	464,468		Oct 07 05:33 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 16 '24	Sale	30.97	3,155	97,717	7,347	Sep 18 04:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 16 '24	Sale	30.97	1,972	61,077	95,608	Sep 18 04:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 11 '24	Sale	30.32	1,620	49,118	7,646	Sep 13 04:33 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 11 '24	Sale	30.32	996	30,199	97,580	Sep 13 04:33 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 09 '24	Sale	29.46	1,590	46,837	7,806	Sep 11 04:15 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 09 '24	Sale	29.46	996	29,339	98,576	Sep 11 04:15 PM
Derek Maetzold	Officer	Sep 09 '24	Proposed Sale	29.33	20,583	603,699		Sep 09 05:18 PM
BRADBURY DANIEL	Director	Sep 05 '24	Sale	29.02	7,867	228,332	7,125	Sep 09 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 03 '24	Sale	30.05	699	21,004	8,005	Sep 05 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 04 '24	Sale	30.02	500	15,012	7,956	Sep 05 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 03 '24	Sale	30.05	417	12,530	99,870	Sep 05 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 04 '24	Sale	30.02	298	8,947	99,572	Sep 05 04:07 PM
Oelschlager Kristen M	Chief Operating Officer	Sep 03 '24	Sale	29.21	5,832	170,330	134,841	Sep 05 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 29 '24	Sale	30.07	2,246	67,548	8,126	Sep 03 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 29 '24	Sale	30.07	1,334	40,120	100,609	Sep 03 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 30 '24	Sale	30.10	539	16,223	8,073	Sep 03 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 30 '24	Sale	30.10	322	9,692	100,287	Sep 03 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 23 '24	Sale	30.09	1,746	52,535	8,356	Aug 27 04:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 23 '24	Sale	30.09	1,037	31,202	102,019	Aug 27 04:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 26 '24	Sale	30.05	128	3,846	8,342	Aug 27 04:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 26 '24	Sale	30.05	76	2,284	101,943	Aug 27 04:11 PM
Derek Maetzold	Officer	Aug 23 '24	Proposed Sale	29.57	44,380	1,312,317		Aug 23 05:17 PM
BRADBURY DANIEL	Director	Aug 12 '24	Sale	26.65	7,883	210,058	8,550	Aug 14 04:53 PM
Stokes Frank	Chief Financial Officer	Aug 07 '24	Sale	25.70	10,000	256,997	30,823	Aug 13 06:13 PM
Daniel Bradbury	Officer	Aug 12 '24	Proposed Sale	26.75	15,750	421,312		Aug 12 04:37 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 01 '24	Sale	23.06	12,989	299,503	132,836	Aug 05 04:16 PM
Stokes Frank	Officer	Aug 07 '24	Proposed Sale	20.92	10,000	209,200		Aug 02 03:13 PM
Oelschlager Kristen M	Chief Operating Officer	Jul 29 '24	Sale	22.06	2,793	61,622	145,825	Jul 31 04:50 PM
Oelschlager Kristen M	Chief Operating Officer	Jul 01 '24	Sale	21.22	2,793	59,279	148,618	Jul 03 04:15 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 03 '24	Sale	23.40	3,968	92,857	8,525	Jun 05 05:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 03 '24	Sale	23.40	2,368	55,416	57,893	Jun 05 05:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 14 '24	Sale	24.27	3,968	96,290	8,911	May 16 04:20 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 14 '24	Sale	24.27	2,368	57,463	60,261	May 16 04:20 PM
BRADBURY DANIEL	Director	May 06 '24	Sale	24.64	23,323	574,679	9,981	May 08 04:51 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 06 '24	Sale	24.72	3,968	98,089	9,297	May 08 04:47 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 06 '24	Sale	24.72	2,368	58,537	62,629	May 08 04:47 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 23 '24	Sale	20.11	705	14,177	9,683	Apr 25 04:54 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 23 '24	Sale	20.11	421	8,466	64,997	Apr 25 04:54 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 12 '24	Sale	20.35	3,263	66,402	9,752	Apr 16 04:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 12 '24	Sale	20.35	1,947	39,621	65,418	Apr 16 04:46 PM
BRADBURY DANIEL	Director	Apr 08 '24	Sale	20.45	2,400	49,087	17,944	Apr 10 04:35 PM
BRADBURY DANIEL	Director	Apr 05 '24	Sale	20.86	11,771	245,543	18,763	Apr 08 04:31 PM
BRADBURY DANIEL	Director	Apr 04 '24	Sale	21.45	9,152	196,310	22,782	Apr 08 04:31 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 03 '24	Sale	21.70	3,968	86,106	10,069	Apr 05 04:37 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 03 '24	Sale	21.70	2,368	51,386	67,365	Apr 05 04:37 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 20 '24	Sale	20.27	3,847	77,979	10,467	Mar 22 05:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 20 '24	Sale	20.27	2,295	46,520	69,806	Mar 22 05:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 21 '24	Sale	20.70	121	2,505	10,455	Mar 22 05:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 21 '24	Sale	20.70	73	1,511	69,733	Mar 22 05:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 07 '24	Sale	20.77	3,996	82,997	10,841	Mar 11 05:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 07 '24	Sale	20.77	2,372	49,266	72,101	Mar 11 05:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 05 '24	Option Exercise	3.72	10,686	39,752	78,604	Mar 06 05:58 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 05 '24	Sale	21.41	4,131	88,461	74,473	Mar 06 05:58 PM
BRADBURY DANIEL	Director	Mar 04 '24	Sale	20.68	23,323	482,285	25,907	Mar 06 05:52 PM
BRADBURY DANIEL	Director	Feb 07 '24	Sale	23.20	2,074	48,117	33,870	Feb 09 04:49 PM
BRADBURY DANIEL	Director	Feb 06 '24	Sale	23.63	9,847	232,685	34,578	Feb 07 04:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CSTL

Castle Biosciences Inc

Upgrade your FINVIZ experience